1. Home
  2. ELVN vs BRKL Comparison

ELVN vs BRKL Comparison

Compare ELVN & BRKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • BRKL
  • Stock Information
  • Founded
  • ELVN 2016
  • BRKL 1871
  • Country
  • ELVN United States
  • BRKL United States
  • Employees
  • ELVN N/A
  • BRKL N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • BRKL Savings Institutions
  • Sector
  • ELVN Health Care
  • BRKL Finance
  • Exchange
  • ELVN Nasdaq
  • BRKL Nasdaq
  • Market Cap
  • ELVN 927.8M
  • BRKL 897.3M
  • IPO Year
  • ELVN 2020
  • BRKL 1998
  • Fundamental
  • Price
  • ELVN $18.42
  • BRKL $10.55
  • Analyst Decision
  • ELVN Strong Buy
  • BRKL Buy
  • Analyst Count
  • ELVN 4
  • BRKL 2
  • Target Price
  • ELVN $39.25
  • BRKL $15.25
  • AVG Volume (30 Days)
  • ELVN 260.6K
  • BRKL 480.1K
  • Earning Date
  • ELVN 05-13-2025
  • BRKL 04-23-2025
  • Dividend Yield
  • ELVN N/A
  • BRKL 5.12%
  • EPS Growth
  • ELVN N/A
  • BRKL N/A
  • EPS
  • ELVN N/A
  • BRKL 0.82
  • Revenue
  • ELVN N/A
  • BRKL $338,567,000.00
  • Revenue This Year
  • ELVN N/A
  • BRKL $55.27
  • Revenue Next Year
  • ELVN N/A
  • BRKL $37.40
  • P/E Ratio
  • ELVN N/A
  • BRKL $12.85
  • Revenue Growth
  • ELVN N/A
  • BRKL N/A
  • 52 Week Low
  • ELVN $13.30
  • BRKL $8.01
  • 52 Week High
  • ELVN $30.03
  • BRKL $13.15
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 47.86
  • BRKL 52.01
  • Support Level
  • ELVN $17.76
  • BRKL $10.55
  • Resistance Level
  • ELVN $20.79
  • BRKL $10.81
  • Average True Range (ATR)
  • ELVN 1.37
  • BRKL 0.28
  • MACD
  • ELVN 0.12
  • BRKL 0.08
  • Stochastic Oscillator
  • ELVN 45.39
  • BRKL 77.44

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About BRKL Brookline Bancorp Inc.

Brookline Bancorp Inc operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.

Share on Social Networks: